Navigation Links
Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies
Date:1/11/2010

7 out of the 25 top pharmas now use Genedata Screener for High Content Screening analysis.

(PRWEB) January 11, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that over the past 12 months Genedata Screener has experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener for High Content Screening (HCS) analysis. Screener's HCS capabilities support complex multiplexed assay formats, enable comparative visualization of HCS images and help standardize processes from a centrally managed platform. The announcement was made at the 7th Annual High Content Analysis Conference where Genedata is presenting and exhibiting (January 11 - 15; Fairmont Hotel - Booth # 27).

"HCS analysis within a high throughput screening infrastructure is evolving and 2009 proved to be the year in which we saw leading pharmaceutical companies understand how they can use Screener's HCS capabilities in conjunction with their high throughput screening workflows," said Dr. Othmar Pfannes, CEO of Genedata. "These companies have quickly transitioned from the learning - enlightenment phase to actual production in which data analysis is no longer a bottleneck in high content screening."

Genedata customers, who rely on Screener for high content confirmation and secondary screens, are beginning to use Screener for HCS at high throughputs. Several customers report that Screener HCS enables them to easily process 1,000,000 compounds or more per screen. This is a result of Screener's ability to leverage this information within a scalable framework, which features automated data processing and intelligent management functions - all of which can be reviewed by scientists at any stage in the process. "2009 was a banner year for HCS adoption," continued Pfannes, "and I project that 2010 will be the year in which we see HCS in far more rigorous production settings as well as continued adoption by customers looking for a scalable HCS technology."

Screener standardizes and automates in-depth analysis of high content screens passing from single-cell data to hit selection in a highly efficient workflow. The increased throughput of Screener HCS and user-friendly interface for visualization, management, and review allows researchers and scientists to review more cellular images in less time and quickly identify subtle variances. While Screener is fully compatible with the Thermo Scientific Cellomics Store image management system, it has also been integrated with other in-house and commercial HCS image storage solutions.

Note to Editors: Genedata will deliver a presentation on how to establish a routine application of HCS in high throughput screening at HCA on January 13th at 1:00 p.m. To schedule an editorial briefing, email Jackie.Thrasivoulos@genedata.com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher, Genedata Screener, and Genedata Expressionist make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

###

Read the full story at http://www.prweb.com/releases/genedata_screener/hca_conference/prweb3424604.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities
2. Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine
3. Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT
4. Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project
5. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):